Immuneering Corp Share Price Today: Live Updates & Key Insights

Immuneering Corp share price today is $5.04, up 3.29%. The stock opened at $4.86 against the previous close of $4.86, with an intraday high of $5.03 and low of $4.76.

Immuneering Corp Share Price Chart

Immuneering Corp

us-stock
To Invest in {{usstockname}}
us-stock

Immuneering Corp Share Price Performance

$5.04 0.0329(3.29%) IMRX at 23 Mar 2026 01:39 PM Biotechnology
Lowest Today 4.76
Highest Today 5.03
Today’s Open 4.86
Prev. Close 4.86
52 Week High 10.08
52 Week Low 1.10
Day’s Range: Low 4.76 High 5.03
52-Week Range: Low 1.10 High 10.08
1 day return -
1 Week return +0.8
1 month return +0.4
3 month return -15.35
6 month return -42.77
1 year return +186.78
3 year return -50.98
5 year return -72.44
10 year return -

Immuneering Corp Institutional Holdings

FMR Inc 14.98

Fidelity Growth Compy Commingled Pl S 6.01

HBM Healthcare Investments AG Ord 5.64

Fidelity Growth Company Fund 4.40

Sanofi 4.19

Vanguard Group Inc 3.97

State Street® SPDR® S&P® Biotech ETF 3.37

T. Rowe Price Associates, Inc. 2.78

Vanguard Total Stock Mkt Idx Inv 2.51

ExodusPoint Capital Management, LP 2.35

Fidelity Select Biotechnology 2.00

Logos Global Management LP 1.47

Fidelity Growth Company K6 1.26

Fidelity Series Growth Company 1.17

Marshall Wace Asset Management Ltd 1.10

US Small-Cap Growth II Equity Comp 1.08

BlackRock Inc 1.05

Blue Owl Capital Holdings LP 1.03

Geode Capital Management, LLC 0.96

Vanguard Institutional Extnd Mkt Idx Tr 0.92

Occam Crest Management L.P. 0.77

iShares Biotechnology ETF 0.56

iShares Core S&P Total US Stock Mkt ETF 0.52

Burkehill Global Management, LP 0.46

Morgan Stanley - Brokerage Accounts 0.46

Fidelity Extended Market Index 0.44

SOUTHPORT MANAGEMENT, L.L.C. 0.43

T. Rowe Price New Horizons Tr-A 0.42

Diametric Capital, LP 0.39

DCF Advisers, LLC 0.33

Two Sigma Investments LLC 0.32

Nowo Global Fund A (SEK) 0.31

State Street Corp 0.27

Qube Research & Technologies 0.26

Renaissance Technologies Corp 0.24

Blackrock Extended Mkt Fund CF 0.23

iShares Micro-Cap ETF 0.22

Extended Equity Market Fund K 0.20

Fidelity Total Market Index 0.16

Direxion Daily S&P Biotech Bull 3X ETF 0.14

Immuneering Corp Market Status

Strong Buy: 2

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

Immuneering Corp Fundamentals

Market Cap 324.56 M

PB Ratio 1.4796

PE Ratio 0.0

Enterprise Value 154.26 M

Total Assets 231.99 M

Volume 7292770

Immuneering Corp Company Financials

Annual Revenue FY23:455 0.0M, FY22:316952 0.3M, FY21:2079961 2.1M, FY20:2311535 2.3M, FY19:1919709 1.9M

Annual Profit FY23:455 0.0M, FY22:158830 0.2M, FY21:926888 0.9M, FY20:1031210 1.0M, FY19:696739 0.7M

Annual Net worth FY23:-51633691 -51.6M, FY22:-49281797 -49.3M, FY21:-33535748 -33.5M, FY20:-17039898 -17.0M, FY19:-8060750 -8.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-86158 -0.1M, Q2/2025:-91844 -0.1M, Q1/2025:-175761 -0.2M, Q3/2024:null 0.0M, Q2/2024:-175482 -0.2M

Quarterly Net worth Q3/2025:-14964875 -15.0M, Q2/2025:-14433881 -14.4M, Q1/2025:-15046132 -15.0M, Q3/2024:-14597366 -14.6M, Q2/2024:-14079927 -14.1M

About Immuneering Corp & investment objective

Company Information Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 53

Industry Biotechnology

CEO Dr. Benjamin J. Zeskind M.B.A., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Immuneering Corp FAQs

What is the share price of Immuneering Corp today?

The current share price of Immuneering Corp is $5.04.

Can I buy Immuneering Corp shares in India?

Yes, Indian investors can buy Immuneering Corp shares by opening an international trading and demat account with Motilal Oswal.

How to buy Immuneering Corp shares in India?

You can easily invest in Immuneering Corp shares from India by:

Can I buy fractional shares of Immuneering Corp?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Immuneering Corp?

Immuneering Corp has a market cap of $324.56 M.

In which sector does Immuneering Corp belong?

Immuneering Corp operates in the Biotechnology sector.

What documents are required to invest in Immuneering Corp stocks?

To invest, you typically need:

What is the PE and PB ratio of Immuneering Corp?

The PE ratio of Immuneering Corp is N/A and the PB ratio is 1.48.